

CURRICULUM VITAE
Lori A. Daiello Pharm.D, ScM
lori_daiello@brown.edu

EDUCATION

1982-1986 B.S., Pharmacy, The Ohio State University, Columbus, OH,
1990-1993 Pharm.D, The Ohio State University Columbus, OH
2009-2012 Sc.M., Epidemiology, Brown University School of Public Health, Providence, RI

POSTGRADUATE TRAINING

2006-2008 T-32 Dementia Research Fellowship, Alpert Medical School
Alzheimer's Disease & Memory Disorders Center, Rhode Island Hospital
Providence, RI

AWARDS AND HONORS

1996 Award for Excellence and Contributions to Pharmacy Practice
The Ohio State University College of Pharmacy, Columbus, OH
1997 Outstanding Faculty Award University of Florida, Orlando, FL
Working Professional PharmD Program
2000 Outstanding Faculty Award University of Florida, Orlando, FL
Working Professional PharmD Program
2004 Professional Impact Award, Alzheimer's Resource Center, Orlando, FL
2004 Best Pharmacists in America
2007 Young Investigators Award, Clinical Science Category
15th Annual Lifespan Research Celebration, Providence, RI
2008 3rd Annual Senior Care Pharmacist Award
American Society of Consultant Pharmacists
2020 7th Perioperative Neurotoxicity Conference Travel Award, Barcelona, Spain
Alzheimer's Association International Society to Advance Alzheimer's
Research and Treatment, Perioperative Neurocognition Special Interest Group

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

1996-2010 Board of Pharmaceutical Specialties, Psychiatric Pharmacy
1996-present Florida Pharmacist License
2009-present Rhode Island Pharmacist License

ACADEMIC APPOINTMENTS

1986-1996 Clinical Instructor, The Ohio State University College of Pharmacy,
Columbus, OH
1997-2000 Clinical Instructor, University of Florida, Orlando, FL

Working Professional Pharm.D Program

2009-2019 Assistant Professor of Neurology (Research), Warren Alpert Medical School of Brown University, Providence, RI

2012-2019 Assistant Professor of Health Services, Policy & Practice (Research), Brown University School of Public Health, Providence, RI

July 2019 - Associate Professor of Neurology (Research), Warren Alpert Medical School of Brown University, Providence, RI

July 2019 - Associate Professor of Health Services, Policy & Practice (Research), Brown University School of Public Health, Providence, RI

HOSPITAL APPOINTMENTS

2008-2016 Research Associate II, Alzheimer's Disease and Memory Disorders Center, Rhode Island Hospital, Providence, RI

2017-2019 Research Scientist, Alzheimer's Disease and Memory Disorders Center, Rhode Island Hospital, Providence, RI

2020-present Senior Research Scientist, Alzheimer's Disease and Memory Disorders Center, Rhode Island Hospital, Providence, RI

OTHER APPOINTMENTS

1986-1996 Clinical Consultant Pharmacist, NCS Healthcare

1988-1993 Consultant Pharmacist, NCS Healthcare

1991-1993 Staff Pharmacist, The Ohio State University Hospitals, Columbus, OH

1993-1996 Pharmacopsychiatric Clinical Specialist, NCS Healthcare

1995-1996 Ohio Department of Mental Health Long Term Care Behavioral Task Force

1996-2000 Clinical Coordinator and Psychopharmacology Specialist
Orlando Regional Healthcare, Senior Services Division

1998-1999 Advisor, State of Florida Panel for the Study of End-of-Life Care

1999-2002 Member, Joint Scientific Advisory Committee on Psychiatric Services in Long Term Care

2000-present President and Psychopharmacology Specialist, Pharmacotherapy Solutions

2001 Psychopharmacology Consultant, Orlando Regional Memory Disorders Clinic, Orlando, FL

2012-2013 Member, Long Term Care Technical Expert Panel, Psychotropic Drug Prescribing Quality Measures for Minimum Data Set and Medicare Part D

2012-present Member, Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment, Perioperative Cognition Special Interest Group

2012-2013 Member, Member, Research Subcommittee, Rhode Island Alzheimer's Disease State Plan

2013-2014 Member, American Academy of Neurology, Neuropharmacoeconomic Work Group

2015-2017 Co-Chair, Bi-Annual Rhode Island Alzheimer's Disease Research Conference

2015-present Investigator, Alzheimer's Disease Neuroimaging Initiative (ADNI)

2015-present Member, Editorial Board, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

2017-present Member, New England Regional Alzheimer's Association MedSci Committee

2018-present Advisor, Global Council on Brain Health.
Consensus statement: Role of Mental Wellbeing on Cognitive Health in Aging

JOURNAL REVIEWER

2009-present Journal of the American Geriatrics Society
2010-present Journal of the American Medical Directors Association
2010-present Alzheimer's & Dementia
2011-present Current Drug Safety
2011-present Journal of Geriatrics
2012-present European Journal of Neurology
2012-present BMC Geriatrics
2013-present Journal of Neurology and Psychology
2015-present Alzheimer's & Dementia, Diagnosis, Assessment, & Disease Monitoring
2019-present Annals of Internal Medicine
2020-present BMJ Open
2020-present Journal of Clinical Psychopharmacology

GRANT REVIEWER

2014-2016 Network for Investigating Delirium: Unifying Scientists (NIDUS),
Cedartree Annual Delirium Bootcamp
2015-2016 American Society of Consultant Pharmacist, Innovation in Senior Care Pharmacy
Awards

MEMBERSHIP IN SOCIETIES

1986-present American Society of Consultant Pharmacists
1994-1995 Member, Educational Advisory Committee
1998-1999 Member, Educational Advisory Committee
1999-2000 Chair, Educational Advisory Committee
2001-2003 Board of Directors
2015-2020 Board of Trustees, ASCP Foundation
2000-present College of Psychiatric and Neurologic Pharmacists
2010-present Alzheimer's Association International Society to Advance Alzheimer's Research
and Treatment (ISTAART)
2012-present ISTAART Perioperative Neurocognition Special Interest Group
2014-present Board of Directors, Alzheimer's Association, Rhode Island Chapter
2019-present American Delirium Society

PUBLICATIONS LIST

Original Publications in Peer-Revised Journals

1. **Daiello LA.** Cholinesterase inhibitors for the treatment of Alzheimer's disease: a review for the consultant pharmacist. Consult Pharm 2001;16:1137-50.

2. Ryan JM, Kidder SW, **Daiello LA**, Tariot PN. Psychopharmacologic interventions in nursing homes: What do we know and where should we go? *Psychiatr Serv* 2002 Nov;53(11):1407-13
3. Golden AG, **Daiello LA**, Silverman MA, Llorente M, Preston RA. University of Miami Division of Clinical Pharmacology Therapeutic Rounds: Medications used to treat anorexia in the frail elderly. *Am J Ther* 2003;10(4):292-8.
4. **Daiello LA**, Beier MT, Hoffman VP, Kennedy JS. Pharmacotherapy of behavioral and psychological symptoms of dementia: A review of atypical antipsychotics. *Consult Pharm* 2003;18:138-57.
5. **Daiello LA**. Atypical antipsychotics for dementia-related behaviors. *Applied Neurology* 2007;3(10):16-22.
6. Ott BR, Heindel WC, Papandonatos GD, Festa EK, Davis JD, **Daiello LA**, Morris JC. A longitudinal study of drivers with dementia. *Neurology* 2008;70(14):1171-8.
7. Jalbert JJ, **Daiello LA**, Lapane KL. The epidemiology of dementia of the Alzheimer's type: A review. *Epidemiologic Rev* 2008;30:15-34.
8. **Daiello LA**, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore D. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. *Am J Geriatric Pharmacotherapy* 2009; 7:74-83.
9. Ott BR, **Daiello LA**. How does dementia affect driving in older patients? *Aging Health* 2010;6:77-85.
10. **Daiello LA**, Ott BR, Festa EK, Miller LA, Heindel WC. Effect of cholinesterase inhibitors on visual attention in drivers with mild Alzheimer's Disease, *J Clin Psychopharmacology* 2010; 30(3):245-51.
11. Parsons C, Alldred D, **Daiello LA**, et al. Prescribing for older people in nursing homes: strategies to improve prescribing and medicines use in nursing homes. *International Journal of Older People Nursing* 2011;6:55-62.
12. Lapane KL, Hughes CM, **Daiello LA**, Cameron KA, Feinberg J. Impact of a Pharmacist-Led Multi-component Intervention Focusing on the Medication Monitoring Phase to Prevent Potential Adverse Drug Events in Nursing Homes. *J Am Geriatr Soc.* 2011; 59:1238-45.
13. Jalbert JJ, **Daiello LA**, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. *Am J Geriatr Pharmacother.* 2011;9:153-63.

14. Lapane KL, Hughes CM, **Daiello LA**, Cameron KA, Feinberg J. Impact of information technology in the medication monitoring phase to prevent adverse drug events in nursing homes. *J Am Med Dir Assoc*. 2011;12:355-63.
15. Daniels AH, **Daiello LA**, Lareau CR, Born CT, et al. Preoperative cognitive impairment, pain, and psychological stress in hospitalized elderly patients awaiting surgery for hip fracture. *Am J Orthop (Belle Mead NJ)*. 2014;43:E146-52.
16. **Daiello LA**, Gardner R, Epstein-Lubow G, Butterfield K, Gravenstein S. Association of dementia with early rehospitalization among Medicare beneficiaries. *Arch Gerontol Geriatr*. 2014;59 (1):162-8.
17. **Daiello LA**, Gongvatana W, Dunsiger S, Cohen R, Ott BR. Association of fish oil use with preservation of brain volume and cognitive function. *Alzheimers Dement* 2015;11:226-35.
18. Ott BR, **Daiello LA**, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Intern Med* 2015;30:348-58.
19. Dahabreh IJ, Adam GP, Halladay CW, Steele DW, **Daiello LA**, Wieland LS, Zgodic A, Smith BT, Herliczek TW, Shah N, Trikalinos TA. Diagnosis of right lower quadrant pain and suspected acute appendicitis [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
20. Snyder PJ, Lim YY, Schindler R, Ott BR, Salloway S, **Daiello LA**, Getter C, Gordon CM, Maruff P. Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults. **Alzheimers Dement**. 2014 Mar;10(2):262-7.
21. Zullo AR, Dore DD, **Daiello L**, Baier RR, Gutman R, Gifford DR, Smith RJ. National trends in treatment initiation for nursing home residents with diabetes mellitus, 2008 to 2010. *J Am Med Dir Assoc*. 2016 Jul 1;17(7):602-8.
22. Steinman MA, Zullo AR, Lee Y, **Daiello LA**, Boscardin WJ, Dore DD, Gan S, Fung K, Lee SJ, Komaiko KD, Mor V. Association of β -blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. *JAMA Intern Med*. 2017 Feb 1;177(2):254-262.
23. Zullo AR, Lee Y, **Daiello LA**, Mor V, John Boscardin W, Dore DD, Miao Y, Fung KZ, Komaiko KDR, Steinman MA. Beta-blocker use in U.S. nursing home residents after myocardial infarction: a national study. *J Am Geriatr Soc*. 2017 Apr;65(4):754-762.
24. Berry SD, Zullo AR, McConeghy K, Lee Y, **Daiello L**, Kiel DP. Defining hip fracture with claims data: outpatient and provider claims matter. *Osteoporosis Int* 2017 Jul;28(7):2233-2237.

25. Berry SD, Zullo AR, Lee Y, Mor V, McConeghy KW, Banerjee G, D'Agostino RB, **Daiello L**, Dosa D, Kiel DP. Fracture risk assessment in long-term care (FRAIL): development and validation of a prediction model. *J Gerontol A Biol Sci Med Sci*. 2017 Aug. [Epub ahead of print].
26. McConeghy KW, Lee Y, Zullo AR, Banerjee G, **Daiello L**, Dosa D, Kiel DP, Mor V, Berry SD. Influenza illness and hip fracture hospitalizations in nursing home residents: are they related? *J Gerontol A Biol Sci Med Sci*. 2018 Nov 10;73(12):1638-1642. doi: 10.1093/gerona/glx200.
27. Zullo AR, Sharmin S, Lee Y, **Daiello LA**, Shah NR, Boscardin JW, Dore DD, Lee SJ, Steinman MA. Secondary prevention medication use after myocardial infarction in U.S. nursing home residents. *J Am Geriatr Soc* 2017 Nov;65(11):2397-2404.
28. Berry SD, Zullo AR, McConeghy K, Lee Y, **Daiello L**, Kiel DP. Administrative health data: guilty until proven innocent. Response to comments by Levy and Sobolev. *Osteoporos Int* 2018 Jan;29(1):255-256. doi: 10.1007/s00198-017-4244-4. Epub 2017 Oct 6.
29. Zullo AR, Zhang T, Beaudoin FL, Lee Y, McConeghy KW, Kiel DP, **Daiello LA**, Mor V, Berry SD. Pain treatments after hip fracture among older nursing home residents. *J Am Med Dir Assoc* 2018 Feb;19(2):174-176. doi: 10.1016/j.jamda.2017.11.008. Epub 2017 Dec 26.
30. Zullo AR, Zhang T, Banerjee G, Lee Y, McConeghy KW, Kiel DP, **Daiello LA**, Mor V, Berry SD. Facility and state variation in hip fracture in US nursing home residents. *J Am Geriatr Soc* 2018 Dec 21. doi: 10.1111/jgs.15725. [Epub ahead of print]
31. Zhang T, Berry SD, Zullo AR, **Daiello LA**, McConeghy K, Lee Y, Kiel DP. Epidemiology of hip fracture in nursing home residents with multiple sclerosis. *Disabil Health J* 2018 Oct;11(4):591-597. doi: 10.1016/j.dhjo.2018.03.002. Epub 2018 Mar 21.
32. De la Monte SM, **Daiello LA**, Hapel AJ, Tong M, Ott BR. Altered serum and cerebrospinal fluid inflammatory cascades in mild cognitive impairment and Alzheimer's disease. *J Neuroinflamm Neurodegen Dis*. 2018;1:1-24.
33. Johanson C, Stopa E, **Daiello LA**, de la Monte S, Keane M, Ott BR. Disrupted blood-cerebrospinal fluid barrier and CSF composition in mild cognitive impairment and Alzheimer's disease, *J Alz Dis & Parkinsonism* 2018;8:435. doi: 10.4172/2161-0460.1000435
34. Reznik ME, Yaghi S, Jayaraman MV, McTaggart RA, Hemendinger M, Mac Grory BC, Burton TM, Cutting SM, Thompson BB, Wendell LC, Mahta A, Potter NS, **Daiello LA**, Kosar CM, Jones RN, Furie KL. Level of consciousness at discharge and associations with outcome after ischemic stroke. *J Neurol Sci*. 2018 Jul 15;390:102-107. doi: 10.1016/j.jns.2018.04.022.

35. **Daiello LA**, Tannenbaum C. Patient-oriented policies to reduce the harmful effects of medication on seniors' brain function. *Public Policy Aging Rep.* 2018 Nov;28(4):124-128. doi: 10.1093/ppar/pry031. Epub 2018 Sep 28.
36. Ott BR, Jones RN, **Daiello LA**, de la Monte SM, Stopa EG, Johanson CE, Denby C, Grammas P. Blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer's disease: relationship to inflammatory cytokines and chemokines. *Front Aging Neurosci* 2018 Aug 21;10:245. doi: 10.3389/fnagi.2018.00245. eCollection 2018.
37. Zullo AR, Hersey M, Lee Y, Sharmin S, Bosco E, **Daiello LA**, Shah NR, Mor V, Boscardin WJ, Berard-Collins CM, Dore DD, Steinman MA. Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β -blockers in older nursing home residents with diabetes after acute myocardial infarction. *Diabetes Obes Metab* 2018 Dec;20(12):2724-2732. doi: 10.1111/dom.13451. Epub 2018 Jul 22.
38. Zullo AR, Zhang T, Lee Y, McConeghy KW, **Daiello LA**, Kiel DP, Mor V, Berry SD. Effect of bisphosphonates on fracture outcomes among frail older adults. *J Am Geriatr Soc* 2018 Dec 21. doi: 10.1111/jgs.15725.
39. Jones RN, Cizginer S, Pavlech L, Albuquerque A, **Daiello LA**, Dharmarajan K, Gleason LJ, Helfand B, Massimo L, Oh E, Okereke OI, Tabloski P, Rabin LA, Yue J, Marcantonio ER, Fong TG, Hshieh TT, Metzger ED, Erickson K, Schmitt EM, Inouye SK; Better Assessment of Illness (BASIL) Study Group. Assessment of Instruments for Measurement of Delirium Severity: A Systematic Review. *JAMA Intern Med.* 2019 Feb 1;179(2):231-239. doi: 10.1001/jamainternmed.2018.6975.
40. De la Monte SM, Tong M, **Daiello LA**, Ott BR. Early-stage Alzheimer's disease is associated with simultaneous systemic and central nervous system dysregulation of insulin-linked metabolic pathways. *J Alzheimer Dis* 2019;68(2):657-668.
41. **Daiello LA**, Racine AM, Yun Gou R, Marcantonio ER, Xie Z, Kunze LJ, Vlassakov KV, Inouye SK, Jones RN, SAGES Study Group: Alsop D, Trivison T, Arnold S, Cooper Z, Dickerson B, Fong T, Metzger E, Pascual-Leone A, Schmitt EM, Shafi M, Cavallari M, Dai W, Dillon ST, McElhaney J, Guttman C, Hshieh T, Kuchel G, Libermann T, Ngo L, Press D, Saczynski J, Vasunilashorn S, O'Connor M, Kimchi E, Strauss J, Wong B, Belkin M, Ayres D, Callery M, Pomposelli F, Wright J, Schermerhorn M, Abrantes T, Albuquerque A, Bertrand S, Brown A, Callahan A, D'Aquila M, Dowal S, Fox M, Gallagher J, Anna Gersten R, Hodara A, Helfand B, Inloes J, Kettell J, Kuczmarska A, Nee J, Nemeth E, Ochsner L, Palihnich K, Parisi K, Puelle M, Rastegar S, Vella M, Xu G, Bryan M, Guess J, Enghorn D, Gross A, Gou Y, Habtemariam D, Isaza I, Kosar C, Rockett C, Tommet D, Gruen T, Ross M, Tasker K, Gee J, Kolanowski A, Pisani M, de Rooij S, Rogers S, Studenski S, Stern Y, Whittmore A, Gottlieb G, Orav J, Sperling R. Postoperative delirium and postoperative cognitive dysfunction: Overlap and Divergence. *Anesthesiology.* 2019 May 24. doi: 10.1097/ALN.0000000000002729.
42. Margolis SA, Zughft Sears M, **Daiello LA**, Solon C, Nakhutina L, Hoogendorn C, Gonzalez JS. Anticholinergic/sedative drug burden predicts worse memory acquisition

- in older racially/ethnically diverse patients with type 2 diabetes mellitus. *Int J Geriatr Psychiatry*. 2019 Jul 17. doi: 10.1002/gps.5173.
43. Miller SC, Cai S, **Daiello LA**, Shireman TI, Wilson IB. Nursing Home Residents by Human Immunodeficiency Virus Status: Characteristics, Dementia Diagnoses, and Antipsychotic Use. *J Am Geriatr Soc*. 2019;67(7):1353-1360. doi: 10.1111/jgs.15949.
 44. Sine K, Lee Y, Zullo AR, **Daiello LA**, Zhang T, Berry SD. Incidence of Lower-Extremity Fractures in US Nursing Homes. *J Am Geriatr Soc*. 2019; 67(6):1253-1257.
 45. Reznik ME, **Daiello LA**, Thompson BB, Wendell LC, Mahta A, Potter NS, Yaghi S, Levy MM, Fehnel CR, Furie KL, Jones RN. Fluctuations of consciousness after stroke: Associations with the confusion assessment method for the intensive care unit (CAM-ICU) and potential undetected delirium. *J Crit Care*. 2019;56:58-62. doi: 10.1016/j.jcrc.2019.12.008.
 46. Reznik ME, Drake J, Margolis SA, Moody S, Murray K, Costa S, Mahta A, Wendell LC, Thompson BB, Rao SS, Barrett AM, Boukrina O, **Daiello LA**, Asaad WF, Furie KL, Jones RN. Deconstructing Poststroke Delirium in a Prospective Cohort of Patients With Intracerebral Hemorrhage. *Crit Care Med*. 2020;48(1):111-118. doi: 10.1097/CCM.0000000000004031.
 47. Reznik ME, Drake J, Margolis SA, Mahta A, Wendell LC, Thompson BB, Rao SS, **Daiello LA**, Furie KL, Jones RN. The authors reply. *Crit Care Med*. 2020 Jul;48(7):e636-e637. doi: 10.1097/CCM.0000000000004402.
 48. Berry SD, **Daiello LA**, Lee Y, Zullo AR, Wright NC, Curtis JR, Kiel DP. Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents. *J Bone Miner Res*. 2020 doi: 10.1002/jbmr.4032.
 49. Reznik ME, Moody S, Murray K, Costa S, Grory BM, Madsen TE, Mahta A, Wendell LC, Thompson BB, Rao SS, Stretz C, Sheth KN, Hwang DY, Zahuranec DB, Schrag M, **Daiello LA**, Asaad WF, Jones RN, Furie KL. The impact of delirium on withdrawal of life-sustaining treatment after intracerebral hemorrhage. *Neurology* 2020;95(20):e2727-e2735. doi: 10.1212/WNL.0000000000010738.
 50. Zullo AZ, Lee YL, Lary C, **Daiello LA**, Kiel DP & Berry SD. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study. *Osteoporos Int*. 2021 Mar;32(3):565-573.
 51. Korthauer LE, Denby C, Molina D, Wanjiku J, **Daiello LA**, Drake JD, Grill JD, Ott BR. Pilot Study of an Alzheimer's Disease Risk Assessment Program in a Primary Care Setting. *Alzheimers Dement (Amst)*. 2021 Feb 20;13(1):e12157. doi: 10.1002/dad2.12157.
 52. Gerlach, LB, Fashaw, S, Strominger, J, Ogarek J, Zullo, AR, **Daiello, LA**, Teno, J, Shireman, TI, and Bynum, JPW. Trends in antipsychotic prescribing among long-term care residents receiving hospice care. *J Am Geriatr Soc*. 2021 Apr 9: doi:

10.1111/jgs.17172.

53. Drake JD, Chambers AB, Ott BR, **Daiello LA**. Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in alzheimer's disease. *Alzheimers Dis*. 2021 Mar 10. doi: 10.3233/JAD-200759.
54. Margolis SA, Kelly DA, **Daiello LA**, Davis J, Tremont G, Pillemer S, Denby C, Ott BR. Anticholinergic/sedative drug burden and subjective cognitive decline in older adults at risk of Alzheimer's disease. *J Gerontol A Biol Sci Med Sci*. 2021 May 22;76(6):1037-1043.
55. Reznik ME, Kalagara R, Moody S, Drake J, Margolis SA, Cizginer S, Mahta A, Rao SS, Stretz C, Wendell LC, Thompson BB, Asaad WF, Furie KL, Jones RN, **Daiello LA**. Common biomarkers of physiologic stress and associations with delirium in patients with intracerebral hemorrhage. *J Crit Care*. 2021 Aug;64:62-67.
56. Cheng S, Banerjee S, **Daiello LA**, Nakashima A, Jash S, Huang Z, Drake JD, Ernerudh J, Berg G, Padbury J, Saito S, Ott BR, Sharma S. Novel blood test for early biomarkers of preeclampsia and Alzheimer's disease. *Nature: Scientific Reports*. In press.

Other Peer-Reviewed Publications

1. **Daiello LA**. "Psychopharmacy in the long-term care setting: A new frontier for pharmacy practice." *Journal of Pharmacy Practice* 1995; 5:228-231.
2. **Daiello, LA**. "Optimizing antidepressant drug therapy: The role of the consultant pharmacist." *The Consultant Pharmacist* 1993;(Suppl A);A31-38.
3. Eckenhoff, RG, for the Perioperative Neurotoxicity Working Group: Avidan MS, Baranov D, Bickler PE, Cibelli M, Crosby GJ, Crowder CM, Culley DJ, **Daiello LA**, et al. Second international perioperative neurotoxicity workshop summary. *Analgesia and Anesthesia* 2011;112:1253-1254.
4. **Daiello LA**. Does omega-3 fatty acid supplementation benefit cognition in Alzheimer's disease or other dementias? A systematic review and meta-analysis of controlled trials [masters thesis]. [Providence (RI)]: Brown University; 2012.

Other Non-Peer Reviewed Publications

1. **Daiello LA**. Atypical antipsychotics for the treatment of dementia-related behaviors: An update. *Med Health R I*. 2007;90(6):191-4.
2. **Daiello LA**. Current issues in dementia pharmacotherapy. *Am J Manag Care* 2007. Dec;13 Suppl 8:S198-202.
3. Gosvenor AM, **Daiello LA**. Memory Protection: A researcher wants to make surgery safer for patients' brains. *Health Discoveries* 2020;3(1):17.

4. Ott BR, **Daiello LA**. My Turn: Remembering the importance of Alzheimer's research during a global pandemic. Providence Journal; June 17, 2020.

Manuscripts Submitted or in Preparation

1. **Daiello LA**, Wang DJ, Jones RN, Boxerman J, Tremont G, O'Bryant S, Kendall M, Cioffi WG, De Oliveira GS, Ott BR, Inouye SK, Blood-brain Barrier Dysfunction and Perioperative Neurocognitive Disorders: Cognitive Recovery After Elective Surgery (CREATES): Study Design and Methods (in preparation)
2. Wang JJ, Zhao X, **Daiello LA**, Boxerman J. Water exchange imaging measurement of blood-brain barrier dysfunction in the CREATES study (in preparation)
3. Kelly DA, Davis JD, **Daiello LA**, Burke E, Fernandez T, Tremont GN, Ott BR, Margolis SA. Neuroticism Moderates the Association between Beliefs about Medications and Reported Adverse Medication Effects in Mild Cognitive Impairment. (Journal of Gerontology: Psychological Sciences; in preparation)

ABSTRACTS

1. Ott BR, Heindel WC, Papandonatos GD, Festa EK, Davis JD, **Daiello LA**, Morris JC. A longitudinal study of drivers with dementia. The 132nd Annual Meeting of the American Neurological Association, Washington, DC, Ann Neurology 62(suppl 11):S22. (October 2007)
2. **Daiello LA**, Ott BR, Festa EK, et al. Cholinesterase inhibitors improve visual attention in drivers with Alzheimer's disease. 15th Annual Lifespan Research Celebration, Providence, RI (November 2007)
3. Smith MM, **Daiello LA**, Davis JD, et al. Prediction of motor vehicle accidents in older drivers enrolled in a study of driving and dementia. National Academy of Neuropsychology Conference (November 2007)
4. **Daiello LA**, Ott BR, Lapane KL, et al. Cholinesterase inhibitor discontinuation is associated with behavioral changes in nursing facility residents American Association for Geriatric Psychiatry Annual Meeting, Orlando, FL (March 2008)
5. **Daiello LA**, Ott BR, Festa EK, et al. Cholinesterase inhibitors improve visual attention in drivers with Alzheimer's disease. International Conference on Alzheimer's Disease, Chicago, IL (July 2008)
6. **Daiello LA**, Ott BR, Festa EK, Miller L, Heindel WC. Cholinesterase inhibitors improve visual attention in drivers with Alzheimer's disease. (Abstract) 25th Anniversary International Conference on Pharmacepidemiology & Therapeutic Risk Management, Providence, RI (August 2009)
7. **Daiello LA**, Gongvatana W, Dunsiger S, et al. Association of pre-baseline fish oil supplement use with rates of brain atrophy and cognitive decline in the Alzheimer's disease

neuroimaging initiative (ADNI) cohort. International Conference on Alzheimer's Disease, Paris, FR (July 2011).

8. Lapane KL, **Daiello LA**, Motzkus C, Parsons C, Hughes CM. Impact of Non-Clinical Factors on Prescribing Decisions in Persons with End-Stage Dementia. Gerontological Society of America, Boston, MA (November 2011).
9. **Daiello LA**, Gardner R, Epstein-Lubow G, Butterfield K, Gravenstein S. Dementia diagnosis increases the risk of 30-day hospital readmission in Medicare beneficiaries. International Conference on Alzheimer's Disease, Vancouver, BC (July 2012).
10. Daniels AH, **Daiello LA**, Badger J, Born CT, et al. Cognitive Assessment After (Hip) Fracture in the Elderly (CAFÉ): Study protocol and selected baseline results of a 12-month prospective cohort study. 20th Annual Lifespan Research Celebration, Providence, RI (October 2012).
11. **Daiello LA**, Daniels AH, Badger J, Lareau CR, Robidoux KA, et al. Association of unrecognized preoperative cognitive impairment with postoperative cognitive and functional outcomes in elderly patients awaiting hip fracture repair. International Conference on Alzheimer's Disease, Boston, MA (July 2013).
12. Ott BR, **Daiello LA**, Springate BA, Bixby K, Murali M, et al. Do statin drugs impair cognition? A systematic review and meta-analysis. International Conference on Alzheimer's Disease, Boston, MA (July 2013).
13. Daniels AH, **Daiello LA**, Lareau CR, Born CT, et al. Preoperative cognitive impairment, pain, and psychological stress in hospitalized elderly patients awaiting surgery for hip fracture. Orthopedic Trauma Association Annual Conference, New Orleans, LA (August 2013).
14. **Daiello LA**, Cizginer S, Pelosi M, Ott BR. Psychoactive medication use and memory impairment among members of an Alzheimer prevention registry. Alzheimers Association International Conference, Washington, DC (July 2015)
15. Stopa EG, Padbury J, **Daiello LA**, Ott BR, Sharma S. Placental tau, α -synuclein, A β and APP levels in pre-eclampsia, and Alzheimer's disease risk factor. Alzheimer's Association International Conference. Washington, D.C., July 18-23, 2015. *Alzheimer's & Dementia*. 11(7):P372 (July 2015)
16. **Daiello LA**, Wellenius G, Ott BR, Buka S. Role of Supplemented DHA for cognition in Alzheimer's Disease and Mild Cognitive Impairment: A systematic review and meta-analysis of randomized controlled trials. Alzheimer's Association International Conference, Washington, DC (July 2015)
17. **Daiello LA**, Stopa EG, Ott BR, de la Monte S, Johanson CE. CNS molecular gradients in mild cognitive impairment and Alzheimer's disease: Implications for blood-brain barrier permeability Alzheimer's Association International Conference, Toronto, CA (July 2016)
18. **Margolis SA**, Daiello LA, Tremont G, Heller B, Denby C, Ott BR. Age moderates the relationship between drug burden index and subjective cognitive decline in members of the

Rhode Island Alzheimer Prevention Registry. National Academy of Neuropsychology 37th Annual Conference, Boston, MA. Arch Clin Neuropsychology 2017;32(6): 656-666.

19. **Daiello LA**, Jones RN, Stopa E, de la Monte S, Johanson CE, Grammas P, Ott BR. Blood brain barrier gradients in mild cognitive impairment and Alzheimer's disease: relationship to inflammatory cytokines and chemokines. Alzheimer's Association International Conference, London, UK (July 2017)
20. Margolis SA, Sears MZ, Solon C, **Daiello LA**, Nakhutina L, Hoogendoorn C, Gonzalez JS. Sedative/anticholinergic drug burden predicts worse memory acquisition in racially/ethnically diverse older adults with Type 2 diabetes. 46th Annual Neuropsychological Association Conference, Washington, DC (February 2018)
21. Reznik ME, Yaghi S, Jayaraman MV, McTaggart RA, Hemendinger M, Mac Grory BC, Burton TM, Cutting SM, Thompson BB, Wendell LC, Mahta A, Potter NS, **Daiello LA**, Kosar CM, Jones RN, Furie KL. Level of consciousness at discharge and associations with outcome after ischemic stroke. American Academy of Neurology Annual Meeting, Los Angeles, CA (April 2018)
22. Drake J, **Daiello LA**, Chambers A, Ott BR. VCAM-1 as a biomarker for cognitive decline in Alzheimer's disease, Alzheimer's Association International Conference, Chicago, IL (July 2018)
23. Miller SC, Cai S, **Daiello LA**, Shireman T, Wilson I. A population perspective of HIV and dementia in nursing homes. Gerontological Society of America, Boston, MA (November 2018)
24. **Daiello LA**, Lee Y, Zullo AR, Zhang T, Berry SD. Trends in the Incidence of Hip Fractures and Post-Fracture Mortality Among U.S. Nursing Home Residents, 2007 to 2013. Gerontological Society of America, Boston, MA (November 2018)
25. Drake JD, Chambers AB, Ott BR, **Daiello LA**. Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in Alzheimer's disease. Alzheimer's Association International Conference (Virtual Conference), Amsterdam, Netherlands (July 2020)
26. Korthauer LE, Denby C, Molina D, Wanjiku J, **Daiello LA**, Drake JD, Grill JD, Ott BR. Implementation of a Targeted Screening Program for Alzheimer's Disease Risk in a Primary Care Setting. Alzheimer's Association International Conference (Virtual Conference), Amsterdam, Netherlands (July 2020)
27. **Daiello LA**, Wang DJ, Jones RN, Boxerman J, Tremont G, O'Bryant S, Kendall M, Cioffi WG, De Oliveira GS, Ott BR, Inouye SK. Blood-brain Barrier Dysfunction and Perioperative Neurocognitive Disorders: Cognitive Recovery After Elective Surgery (CREATES): Study Design and Methods. Alzheimer's Association International Conference (Virtual Conference), Amsterdam, Netherlands (July 2020)

28. Kelly DA, Davis JD, **Daiello LA**, Burke E, Fernandez T, Tremont GN, Ott BR, Margolis SA. Neuroticism Moderates the Association between Beliefs about Medications and Reported Adverse Medication Effects in Mild Cognitive Impairment. Alzheimer's Association International Conference (Hybrid Conference), Denver, Colorado (July 2021)

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. **Daiello LA**. Certification in Geriatric Pharmacy (CGP) Internet Review Program (1999) "Psychopharmacology in the elderly", peer-reviewed web-based course.
2. **Daiello LA**. Certification in Geriatric Pharmacy (CGP) Internet Review Program (2011). "Diagnosis and treatment of Alzheimer's disease" peer-reviewed web-based course. Commissioned by the American Society of Consultant Pharmacists.

INVITED PRESENTATIONS

Regional

1. University of Vermont Dementia and Neuropsychiatry Update (2006) Behavioral Effects of Medications for Dementia, Burlington, VT
2. Massachusetts Long Term Care Clinicians (2006) The Effect of F329 on the Treatment of Psychiatric Illness and Behavioral Symptoms in Long Term Care, Boston, MA
3. American Society of Consultant Pharmacists – NE Chapter Annual Meeting (2007) Diagnostic and Treatment Dilemmas: Depression and Dementia in LTC Settings, Foxwoods, CT
4. Rhode Island Hospital Alzheimer's Disease and Memory Disorders Center Research Meeting (2007) Behavioral Effects of Cholinesterase Inhibitors in Nursing Facility Residents with Dementia, Providence, RI
5. Brown University School of Community Health: FDA Workgroup on Atypical Antipsychotics for Behavioral Symptoms in Dementia (2008) Pharmacologic Treatment Options, Providence, RI
6. Rhode Island Hospital Alzheimer's Disease and Memory Disorders Center Research Meeting (2008) Does Discontinuation of Cholinesterase Inhibitors Exacerbate Behavioral Symptoms in Nursing Home Patients with Dementia? Providence, RI
7. Rhode Island Hospital Alzheimer's Disease and Memory Disorders Center Research Meeting (2009) Do Cholinesterase Inhibitors Improve Visual Attention in Drivers with Alzheimer's Disease? Providence, RI
8. Neurology Grand Rounds, Rhode Island Hospital (2009) General Anesthesia and Postoperative Cognitive Impairment, Providence, RI
9. Neuropsychology Clinical Conference, Butler Hospital (2010) Psychopharmacological Drug Interactions: Part 1, Providence, RI

10. Neurology Fellows Noon Conference, Rhode Island Hospital (2010) Treatment of Behavioral Symptoms in Dementia: An Evidence-Based Review, Providence, RI
11. Research Day, PHP 2610, Brown University (2011) Influence of Statin Drugs on Cognitive Function and Onset of Dementia in the ADNI Cohort, Providence, RI
12. Neuropsychology Clinical Conference, Butler Hospital (2011) Psychopharmacological Drug Interactions: Part 2, Providence, RI
13. Neurology Noon Conference, Rhode Island Hospital (2011) Does Omega-3 Supplementation Benefit Cognition in Older Adults?
14. Geriatric Psychiatry Fellows Conference, Rhode Island Hospital (2012) A Case-Based Approach to Clinically Relevant Psychopharmacologic Drug Interactions in the Elderly, Providence, RI
15. Geriatric Psychiatry Clinical Rounds, VA Medical Center (2012) Drug Interactions and Adverse Effects in the Elderly (2012), Providence, RI
16. Alzheimer's Association, Rhode Island Chapter, Annual Research Lecture (2012) What's Good for the Heart is Good for the Brain? Dietary Supplements for Brain Health and Aging, Providence, RI.
17. Rhode Island Assisted Living Association Annual Meeting (2013) People with Memory Loss and their Medications: A Cautionary Tale, Warwick, RI
18. Neurology Noon Conference (2014) Perioperative Predictors of Postoperative Cognitive Dysfunction Following Non-Cardiac Surgery, Providence, RI.
19. Neurology Research Night (2016) Alzheimer's Disease and Memory Disorders Center Research, Providence, RI.
20. Neurology Noon Conference (2017) Role of Inflammation and Blood-Brain Barrier Disruption in Postoperative Cognitive Decline, Providence, RI.
21. Countdown to 2025: Progress on ending Alzheimer's disease (2017) Newport Hospital, Newport, RI.
22. Countdown to 2025: Progress on ending Alzheimer's disease (2017) Miriam Hospital, Providence, RI
23. Alzheimer's Disease and Age-related Memory Loss – What's the difference? (2019) Cranston Senior Center
24. Alzheimer's Association, Rhode Island Chapter, Caregiver Journey Conference (2020), Does Surgery Cause Memory Loss? Providence, RI

National

1. American Medical Directors Association Annual Meeting (2007) Pharmacology and Management of Dementia in Long Term Care Settings, Hollywood, FL
2. Florida Medical Directors Annual Meeting (2007) Diagnostic and Treatment Dilemmas: Depression and Dementia in LTC Settings, Orlando, FL
3. American Society of Consultant Pharmacists 38th Annual Meeting (2007) Diagnostic and Treatment Dilemmas: Depression and Dementia in LTC Settings, Philadelphia, PA
4. National Association of Geriatric Care Managers Annual Meeting (2008) The Care Manager as Detective: Assessment and Treatment of Behavioral Symptoms in Dementia, Orlando, FL
5. New York Long Term Care Pharmacist Association (2008) Update on the Treatment of Geriatric Depression, Buffalo, NY
6. National Association of Professional Geriatric Care Managers (2009) Treatment of Behavioral Symptoms in Dementia, Chicago, IL
7. University of Pennsylvania, Department of Anesthesia Research Grand Rounds (2010) Post-Operative Cognitive Dysfunction and Anesthesia: Confounder or Cause? Philadelphia, PA
8. Office of Senator Kohl, Committee on Aging (2010) Inappropriate Use of Antipsychotic Drugs in Nursing Home Patients with Dementia, Washington, DC
9. Policy and Practice Section, American Geriatrics Society Annual Scientific Meeting (2012) Alternatives to Antipsychotic Drugs in the Treatment of Dementia-Related Behavioral Symptoms, Seattle, WA
10. Arizona Geriatrics Society, Annual Fall Symposium (2012) Alternatives to Antipsychotics for Behavioral Symptoms: An Evidence-Based Review, Phoenix, AZ.
11. World Elder Abuse Awareness Conference (2013) Dangers of Inappropriate Medication Use in the Elderly, Orlando, FL.
12. American Society of Consultant Pharmacists Annual Meeting (2013) Advances in Antidepressant Therapy for Older Adults, Seattle, WA.
13. Maine Association for Psychiatric Physicians Annual Meeting (2014) Antipsychotics and Alternatives in the Treatment of Behavioral and Psychological Symptoms of Dementia: Evidence and Experience, Freeport, ME.
14. Florida Attorney Generals' Office (2015) Dangers of Inappropriate Medication Use in Older Adults, Orlando, FL.

15. Florida Aging Life Care Professionals Annual Conference (2016) Recognition of Adverse Cognitive Effects of Medication, Orlando, FL.
16. 5th International Workshop of Perioperative Neurotoxicity in the Elderly (2016) Preoperative Nutrition and Postoperative Cognitive Recovery, San Francisco, CA.
17. TEDx Orlando (2016) Thinking Outside the (Pill) Box, Orlando, FL.
18. Orlando Health Community Forum (2017) Can Medications Cause Dementia or Alzheimer's Disease? Orlando, FL.
19. Gerontological Society of America (2018) Trends in Hip Fractures and Post-Fracture Mortality Among U.S. Nursing Home Residents, Boston, MA
20. Society for Neuroscience in Anesthesia and Critical Care (2021) Annual Meeting. Blood-brain barrier, neuroinflammation, and impaired cognitive outcomes. Future Forward Topics in Perioperative Basic Neuroscience, virtual conference.

International

1. Alzheimer's Association International Conference Perioperative Cognitive Disorders Interest Group (2017) Association of Delirium with Postoperative Cognitive Impairment, London, UK.
2. Global Council on Brain Health (2018) Brain Health and Mental Well-Being: Effects of Medications, London, UK.
3. 7th International Workshop on Perioperative Neurotoxicity in Older Adults (2020), Blood-Brain Barrier Dysfunction and Perioperative Cognitive Decline, Barcelona, Spain.*
4. Society for Neuroscience and Critical Care 48th Annual Meeting (2020), Blood-Brain Barrier, Inflammatory Mediators, and Cognitive Outcomes, Montreal, Canada.*

*Conference presentations cancelled due to COVID-19 pandemic

GRANTS

Completed

Orlando Regional Healthcare System 10/01/1999-12/19/2000

Lori Daiello (PI)

Role: Principal Investigator

Total Costs: \$5500

This study is to identify the types and frequency of drug-related problems in patients presenting to a memory disorders clinic.

Administration on Aging/ Orlando Senior Resource Alliance 02/01/2001–12/20/2002

Lori Daiello (PI)

Role: Principal Investigator

Total Costs: \$20,000

This study is to investigate the impact of providing psychopharmacology consultation to high risk elderly residing in the community.

NIH/NIA RO1 AG16335

09/15/2001-05/31/2007

Brian Ott (PI)

Role: Sub-Investigator

Total Costs: \$1,439,916

“A Longitudinal Study of Drivers with Dementia.”

This study is to define the course of driving impairment in Alzheimer’s Disease and develop computerized test predictors of impaired road test performance.

NIH/NIA 2RO1 AG016335

05/15/2007-4/30/2013

Brian Ott (PI)

Role: Sub-Investigator

Total Costs: \$1,783,538

“Naturalistic Assessment of Driving in Cognitively Impaired Elders.”

This study is to define the basis of driving impairment in Alzheimer’s disease and develop computerized test predictors of impaired road test performance and driving ability in the natural home environment.

NIH/AHRQ 1R18 HS017281

09/30/2007 – 8/31/2010

Kate Lapane (PI)

Role: Sub-Investigator

Total Costs: \$1,199,549

“Tailored DVD to Improve Medication Management for Low Literate Elderly Patients.”

This project focuses on developing and testing interventions that seek to improve the patient experience of care through health information technology, improved shared decision making and patient-clinician communication, as well as self-management of chronic conditions.

NIH/AHRQ 1K08 HS017735

07/01/2009-12/31/2014

Lori Daiello (PI)

Role: Principal Investigator

Total Costs: \$706,018

“Neglected by the Evidence: The Intersection between Medical Complexity and Dementia”

The focus of this career development grant is the building of skills in comparative effectiveness research methods and data analysis to investigate the effects of discontinuing cholinesterase inhibitors in nursing home patients with dementia and the effects of general anesthesia on the rate of cognitive and functional decline of nursing home patients with dementia.

Department of Orthopedic Surgery/Rhode Island Hospital

03/30/2011- 05/01/2014

Lori A. Daiello (Co-PI)

Role: Co-principal Investigator

Total Costs: \$50,000

“Cognitive Assessment after (Hip) Fracture in the Elderly (CAFÉ) Study.”
The objective of this study was to investigate pre-and post-operative memory impairment among hip fracture patients.

NIA R03 AG050232 01/01/2016 – 12/31/2018

Lori Daiello (PI)

Role: Principal Investigator

Total Costs: \$178,852

“Inside the Black Box: Culture Change and Behavioral Outcomes in Dementia.”
This research investigates the relationship between culture change-motivated environmental alterations and antipsychotic drug prescribing in a national cohort of nursing home residents with dementia.

NIA R21 AG057451 09/15/17-08/1/2018

Vincent Mor (PI)

Role: Consultant

Total Costs: \$571,156

“Metrical - Music & memory: A Pragmatic Trial for Nursing Home Residents with AD”
The purpose of this research is to rigorously study the effects of an individualized music intervention (Music & Memory™) on anxiety, depression, and behavioral symptoms in nursing home residents with Alzheimer’s disease.

Department of Neurology/Rhode Island Hospital 04/30/18- 3/01/2020

Lori Daiello (PI)

Role: Principal Investigator

Total Costs: \$28,500

The objective of this proposal is to expand the Rhode Island Alzheimer’s Disease Prevention Registry to include banked blood samples for future research, accomplished through the storage of surplus serum and plasma from 200 participants.

NIH/NIGMS 5P20GM119943-03 07/01/2019- 6/30/2020

Peter Quesenberry (PI)

Role: Co-investigator

Total Costs: \$418,804

“Administrative Core COBRE Phase II Stem Cells and Aging”
This supplemental study will examine salivary extracellular vesicles and their role in Alzheimer’s Disease.

Current

Department of Neurology/Rhode Island Hospital 05/30/2018-12/31/2021

Lori A. Daiello (Co-PI)

Role: Co-Principal Investigator

Total Costs: \$21,000

“Detecting Acetylcholinesterase Inhibitor Non-Adherence in Alzheimer’s Disease.”

The objective of this proposal is to validate a brief/novel performance-based simulation of medication management ability in relation to real-world acetylcholinesterase inhibitor medication-taking behavior in patients with mild cognitive impairment and Alzheimer's disease.

NIA 5P01AG027296-12

06/1/2020- 12/31/2021

Theresa Shireman (PI)

Role: Consultant

Total Costs: \$237,153

“Behavioral Control and Alzheimer's Disease: Policies, Medication Use, and Health Effects Across Care Settings”

This project will evaluate substitution of other psychotropic medications for antipsychotic drugs among nursing home residents with dementia; the impact of federal antipsychotic initiatives on assisted living and community dwellers; racial/ethnic differences in drug exposures across settings; and their effects on mortality, stroke, major fractures and psychiatric admissions.

NIA R01 AG061221

07/15/2019- 06/30/2023

Berry, Sarah D (PI)

Role: Consultant

Total Costs: \$2,812,212

“Safe Cardiometabolic Drug Prescribing To Prevent Injury In Nursing Home Residents”

The purpose of this project is to determine the net clinical benefit of cardiometabolic drugs in ADRD and other nursing home residents that will promote deprescribing psychoactive and cardiometabolic drugs and encourage osteoporosis treatment.

NIA R01 AG058648

05/01/2019 – 03/31/2024

Lori A. Daiello (PI)

Role: Principal Investigator

Total Costs: \$3,864,309

“Blood-Brain Barrier Disruption as a Biomarker for Perioperative Neurocognitive Disorders: Cognitive Recovery After Elective Surgery (CREATES) Study.”

The objective of this research is to investigate the extent to which dynamic contrast-enhanced MRI evidence of blood-brain barrier dysfunction predicts the incidence of postoperative delirium and postoperative cognitive decline, in a cohort of older adults undergoing major elective non-cardiac surgeries.

UNIVERSITY TEACHING ROLES

1986-1996 The Ohio State University College of Pharmacy, Columbus, Ohio

Course Instructor: Psychopharmacology

85 Students

Topics: (1) Psychiatric assessment;

(2) Safety and efficacy of psychopharmacologic treatment of schizophrenia and mood disorders;

(3) Treatment of Alzheimer's Disease

- 1997-2000 University of Florida, Working Professional Pharm.D Program,
Tampa, FL
Course Instructor: Geriatric Psychopharmacology
150 Students
Topics: (1) Psychiatric assessment;
(2) safety and efficacy of geriatric Psychopharmacology;
(3) Treatment of Alzheimer's Disease
- 2009-present Alpert Medical School of Brown University, Providence, RI
Lecturer: Programs in Geriatric Psychiatric and Geriatric Medicine, Neurology,
Neuropsychology
Topics: (1) Safety and efficacy of geriatric psychopharmacology;
(2) Assessment and treatment of behavioral symptoms of dementia;
(3) Treatment of Alzheimer's Disease

UNIVERSITY TEACHING, ADVISING and MENTORING ROLES

- 2019 Biotechnology Masters Program
Brown University, Providence, RI
Thesis Advisor to Amy Lin, ScM
Remediating Epigenetic Dysregulation in Alzheimer's Disease

HOSPITAL TEACHING, ADVISING, and MENTORING ROLES

- 2016-2018 Aging and Dementia Fellowship
Rhode Island Hospital, Providence RI
Mentor to Seth Margolis, PhD
- 2017-2018 Aging and Dementia Fellowship
Rhode Island Hospital, Providence RI
Mentor to Jonathan Drake, MD
- 2020-2021 Aging and Dementia Fellowship
Rhode Island Hospital, Providence RI
Mentor to Jamie Bass, MD
- 2020-present Aging and Dementia Fellowship
Rhode Island Hospital, Providence RI
Mentor to Deirdre O'Shea PhD